Adipotide

Quick Facts

Introduction

Adipotide — also referred to as FTPP (fat-targeted proapoptotic peptide) — is an experimental peptide conjugate that takes a fundamentally different approach to fat reduction than the appetite- and metabolism-based compounds elsewhere in this library. Rather than influencing hunger signaling like Semaglutide or Tesofensine, or fat-cell metabolism like AOD-9604, adipotide is studied for its association with selectively destroying the blood supply to white adipose tissue.

The concept behind adipotide grew out of vascular-targeting research originally developed in oncology. Investigators reasoned that fat tissue, like a tumor, depends on its own blood supply to survive, and that a peptide which homes to the vasculature of white fat and triggers cell death there could cause the targeted fat depot to regress. This makes adipotide one of the more mechanistically unusual and aggressive fat-research compounds documented.

This profile covers what adipotide is, the two-part design of its targeting and proapoptotic motifs, its vascular-disruption mechanism, the preclinical fat-mass research it appears in, and how it compares with metabolism- and appetite-based fat compounds. Related entries are catalogued in the peptide database.

What is Adipotide?

Adipotide is a chimeric peptide conjugate built from two functional parts joined together. The first is a homing (targeting) peptide — the sequence CKGGRAKDC — that recognizes a marker expressed on the blood vessels supplying white fat. The second is a proapoptotic motif — a sequence based on the KLAKLAK (D-amino-acid) peptide — that triggers programmed cell death once the conjugate reaches its target.

The logic of the design is address plus payload: the targeting motif acts as the address that directs the molecule to fat vasculature, while the proapoptotic motif is the payload that disrupts the targeted cells. This is the same conceptual architecture used in vascular-targeted cancer research, repurposed here toward adipose tissue rather than tumor tissue.

Molecular and structural characteristics

Structurally, adipotide is a bifunctional conjugate. The CKGGRAKDC homing sequence is a cyclic peptide identified through phage-display screening as binding prohibitin, a protein found to be selectively presented on the endothelial cells of white-adipose-tissue blood vessels. The proapoptotic portion uses D-amino acids in the KLAKLAK motif, which makes the segment resistant to ordinary proteolysis and able to disrupt mitochondrial membranes once internalized.

The two motifs are joined so that the targeting sequence delivers the otherwise non-specific proapoptotic payload only where the address is recognized — confining the cell-killing activity, in principle, to the targeted vasculature rather than acting body-wide.

Mechanism of action

Adipotide's mechanism is anti-vascular rather than metabolic. The CKGGRAKDC homing motif binds prohibitin on the surface of the endothelial cells lining the blood vessels that feed white adipose tissue. Once the conjugate docks at this target, the attached KLAKLAK proapoptotic motif is brought into proximity with the cell, where it disrupts the mitochondrial membrane and triggers apoptosis (programmed cell death) in that endothelial cell.

The downstream consequence studied in preclinical models is the loss of the microvasculature supplying the fat depot. Deprived of its blood supply, the white adipose tissue is reported to regress. This is a fundamentally different route to fat reduction than appetite suppression or stimulated lipolysis — adipotide is studied for removing the tissue's vascular support rather than altering how fat cells signal or metabolize.

Because the proapoptotic payload is intrinsically non-selective, the targeting motif is what confines the effect: the molecule is intended to act only where prohibitin is presented on fat vasculature. The fidelity of that targeting is therefore central to both the rationale and the safety considerations of the approach, and is a major focus of the research.

• Homing motif binds prohibitin on white-fat endothelial cells.
• Proapoptotic motif disrupts mitochondrial membranes upon docking.
• Targeted endothelial cells undergo apoptosis.
• Loss of vascular support is associated with regression of fat depots.

Fat-mass and preclinical research applications

Adipotide's most cited research comes from preclinical primate and rodent models. In studies of obese non-human primates, the targeting conjugate was associated with reductions in body weight and white-fat mass, accompanied by improvements in metabolic markers — observations that drew substantial attention because of the magnitude and the novel anti-vascular mechanism.

Critically, adipotide has not progressed to the robust human clinical evidence base seen with the incretin peptides, and its preclinical profile raised important safety questions — including effects on the kidney, where dehydration and renal changes were noted in animal research. As a result, adipotide remains firmly an experimental research compound, of interest mechanistically rather than as an established intervention. The broader fat-research landscape is catalogued in the peptide database.

Vascular-targeting research context

Adipotide is best understood within the broader research program of ligand-directed vascular targeting, which uses homing peptides identified by phage display to deliver payloads to specific tissue vasculatures. The same platform produced tumor-vasculature-targeting conjugates, and adipotide represents its application to adipose tissue, exploiting the discovery that prohibitin is differentially presented on white-fat blood vessels.

This places adipotide in a different conceptual category from the appetite- and metabolism-based fat compounds. Its scientific interest lies as much in the targeting concept — the idea that a tissue can be reduced by selectively dismantling its blood supply — as in any specific fat-loss endpoint, which is why it continues to be discussed in mechanistic research even where its translational path is uncertain.

Comparison: Adipotide vs AOD-9604 vs Semaglutide

Adipotide is mechanistically unlike the other fat- and weight-research compounds. AOD-9604 targets fat-cell metabolism (lipolysis), and Semaglutide acts on appetite through the GLP-1 receptor; adipotide instead destroys the vasculature supplying fat tissue.

Where AOD-9604 and Semaglutide work through fat metabolism and appetite respectively, adipotide pursues a structural, anti-vascular route. Full entries for each compound are in the peptide database.

Half-life and pharmacokinetic considerations

As a peptide conjugate, adipotide is subject to relatively rapid clearance, and its pharmacokinetics are studied largely in the preclinical context where it was characterized. The use of D-amino acids in the proapoptotic motif confers some resistance to proteolysis, but the conjugate as a whole has a short systemic presence consistent with peptide compounds of its size.

Because much of the published characterization comes from animal studies with specific administration schedules, pharmacokinetic figures are treated as study-specific. The renal handling of the compound is of particular interest given the kidney-related safety signals reported in preclinical research.

Reconstitution and handling considerations

Lyophilized adipotide is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the conjugate. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized adipotide is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled.

Research limitations

Adipotide is among the most experimental compounds in this library. Its evidence base is predominantly preclinical, and animal research flagged meaningful safety considerations — notably renal effects and dehydration — that have limited its translational progress. Its anti-vascular mechanism is inherently more aggressive than appetite- or metabolism-based approaches, making the fidelity of its tissue targeting the central safety question. It is described here strictly for research reference.

• Evidence is predominantly preclinical (primate and rodent models).
• Animal research flagged renal and dehydration safety concerns.
• Anti-vascular mechanism is aggressive and targeting-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004.Source
2. Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011.Source
3. Daquinag AC, et al. Vascular targeting of adipose tissue as an anti-obesity approach. Trends Pharmacol Sci. 2011.Source